|Articles|December 13, 2018

Surrey Clinical Research Centre Signs Five-Year Contract Renewal with OmniComm Systems

Fort Lauderdale, FL, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Surrey Clinical Research Centre, a core human research resource within the Faculty of Health & Medical Sciences at University of Surrey in the United Kingdom, has signed a new five-year renewal contract to use Promasys EDC from OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology.

Surrey Clinical Research, an MHRA Phase I accredited facility with expertise in Phase I, first-in-human, through to Phase IV, has used Promasys since 2014, and the new agreement extends that commitment for an additional five-year period from 2019 to 2024. Surrey CRC is able to advise and execute the complete clinical trials process from start to finish, including protocol design and development, oversight of all regulatory applications, set-up, management and conduct, as well as data management, data analysis and reporting from single-site to global multi-center trials.

The enhanced features and functionality of Promasys 7.4 include improvements to the Lab Connector, Lab Review Module, Sample Tracking, Event Coding and Electronic Signatures - all of which were instrumental in securing the new agreement with Surrey. In addition, PRO workflow capabilities were an added bonus, as Surrey is looking to incorporate patient-reported outcomes in upcoming studies.

“The Surrey Clinical Research Centre is excited to continue and develop their well-established working relationship with OmniComm. The Promasys EDC system has been an excellent asset for both our clinical trial and academic research projects,” said Vikki Revell, Ph.D., head of Research and Study Management at Surrey Clinical Research Centre.

Promasys is an integrated clinical data management and EDC system that brings industry standard quality and efficiency to data collection and data management in clinical trials. Built on a history of innovation spanning almost 30 years and utilized in more than 1,000 clinical trials around the globe, Promasys has become the data management and EDC solution of choice for many of the world’s leading academic, medical research and life science organizations.

“We’re delighted to have earned the trust and renewed business commitment from Surrey Clinical Research Centre, especially given that it is one of the most prestigious research institutes in the United Kingdom,” said Kuno van der Post, Ph.D., chief commercial officer of OmniComm.

About Surrey Clinical Research Centre
Surrey CRC has a prestigious track record of over 15 years’ experience undertaking clinical trials in both participant and patient populations from Phase I, first-in-human, through to Phase IV. In addition to working with leading pharmaceutical companies, Surrey CRC collaborates with small biotech organisations, charitable organisations, basic science and clinical academic colleagues on a range of studies including CTIMP, medical device and interventional studies. Surrey CRC has particular expertise in sleep, psychopharmacology, circadian rhythms, chronopharmacology, oncology, immunology, vaccines and early phase studies in healthy participants. Please visit https://crc.surrey.ac.uk/ for more information.

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information, and follow OmniComm on Twitter: @OmniCommSystems, on LinkedIn: @OmniComm Systems and Facebook: @OmniComm Systems, Inc.

Trademarks
OmniComm, Promasys, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.

Contact InfoKuno van der Post, Ph.D. OmniComm Systems, Inc. +1.954.473.1254KvanderPost@omnicomm.com

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 6th, 2026

What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to the region.

November 6th, 2026

ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment

In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.

Ten key risk indicators can flag recurring good clinical practice problems in noncompliance, safety, data quality, and oversight, but only when normalization, trial timing, and combined signals are taken into account. Credit: Stock.Adobe.com/Andrey Popov.

November 6th, 2026

The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent

Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

November 5th, 2026

Why Outdated Perceptions of APAC Clinical Trial Sites Persist Among Smaller Biotechs

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how regulatory reform and inspection data contradict the view that APAC sites are slower or lower quality, and why sponsors need to update their assumptions.

November 5th, 2026

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health

In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.

November 5th, 2026

ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal

In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.

November 4th, 2026

Comparing OpenAI and Mistral on Clinical Trial Matching

Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.

November 4th, 2026

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time

In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.